Method for treating steatohepatitis with A-54556A to non-human subjects
A-54556A addresses mitochondrial dysfunction in NASH by restoring ClpP activity, effectively reducing fatty liver and inflammation, and inhibiting fibrosis, providing a therapeutic approach for NASH.
Patent Information
- Application Number
- KR1020240186913
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-12-16
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2041-03-31
AI Technical Summary
Current treatments for non-alcoholic steatohepatitis (NASH) and associated fatty liver diseases do not effectively address mitochondrial dysfunction, leading to progressive liver damage and increased risk of chronic conditions like liver cirrhosis and cancer.
Administering A-54556A, a ClpP activator, to restore mitochondrial protease activity and reduce fatty liver, inflammation, and fibrosis in non-human subjects.
A-54556A restores ClpP expression and activity, reducing fatty liver, suppressing inflammation, and inhibiting liver fibrosis, thereby treating or preventing NASH.
Smart Images

Figure 112024139114526-PAT00004_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a method for treating fatty liver disease by administering A-54556A to a non-human individual. Background Technology
[0003] Globally, the number of patients with metabolic diseases caused by overweight and obesity is continuously increasing. According to Cohen et al. (2011), approximately 34% of the obese adult population in the United States currently has non-alcoholic fatty liver disease (steatosis), and it has been reported that this condition is highly likely to eventually develop into chronic liver diseases such as liver failure, cirrhosis, and hepatocellular carcinoma, which are common chronic diseases. Additionally, according to Stefan et al. (2008) and Cohen et al. (2011), it has been reported that 80% of adults with non-alcoholic fatty liver disease may develop metabolic diseases such as insulin resistance, diabetes, and heart disease.
[0004] Non-alcoholic fatty liver disease includes simple fatty liver disease, in which fat accumulates in the liver independently of alcohol, and non-alcoholic steatohepatitis (NASH). Since non-alcoholic steatohepatitis (NASH) progresses through the stage of simple fatty liver, where fat accumulates in the liver beyond normal limits, and induces inflammatory responses, cellular fibrosis, and cell damage, there is a significantly high likelihood of it progressing to liver cirrhosis or liver cancer.
[0005] Mitochondrial dysfunction is considered a significant factor in the development of non-alcoholic steatohepatitis (NASH). First, genetic and environmental factors induce obesity and insulin resistance, leading to fatty liver syndrome characterized by fat accumulation in liver tissue due to insufficient fatty acid processing capacity. Subsequently, the accumulation of toxic lipid derivatives (diacylglycerols, ceramides, lysophosphatidic acid), excessive oxidative stress, endotoxins, mitochondrial dysfunction, the production of various inflammatory factors (TNF-α and IL-6), and the activation of hepatic stellate cells induce various secondary toxicities, causing hepatocellular damage and ultimately progressing to non-alcoholic steatohepatitis (NASH) (Mota et al, 2016; Alisi A et al, 2011; Jung et al; 2014).
[0006] Mitochondrial chaperones and proteases have been reported to play a crucial role in maintaining protein homeostasis in mitochondria (Jovaisaite, V). In particular, according to Voos et al., ATP-dependent mitochondrial proteases such as protease Lon, the caseinolytic protease complex (ClpXP), and matrix proteases (iAAA and mAAA) play a vital role in maintaining protein homeostasis by detecting and monitoring protein abnormalities within mitochondria and degrading those abnormal proteins. It is hypothesized that dysfunction of these proteases, which regulate protein homeostasis, leads to the accumulation of misfolded proteins in mitochondria, thereby inducing damage to mitochondrial function and causing neuropathy. Inadequate mitochondrial protein quality control resulting from a deficiency of ClpP (caseinolytic protease P) in the mitochondrial matrix can potentially lead to neurological dysfunction. However, to date, no association has been reported between abnormalities in Clp protease and fatty liver or steatohepatitis.
[0007] Furthermore, according to a recent paper (Implications of Mitochondrial Unfolded Protein Response and Mitokines: A Perspective on Fatty Liver Diseases), ClpP knockout mice were created to investigate the association between ClpP and steatohepatitis, but it was reported that the incidence of NASH actually decreased. Therefore, the association between ClpP and non-alcoholic steatohepatitis has not yet been clearly proven. Prior art literature
[0008] U.S. Patent Publication US2016 / 0046674 (2016.02.18) The problem to be solved
[0009] According to one embodiment, the present invention provides a method for treating fatty liver disease by administering A-54556A to a non-human individual. means of solving the problem
[0011] One aspect provides a method for treating fatty liver disease by administering A-54556A to non-human subjects.
[0012] One aspect provides a pharmaceutical composition for the treatment or prevention of fatty liver disease comprising A-54556A or a pharmaceutically acceptable salt thereof as an active ingredient.
[0013] According to one embodiment, liver tissue of mice fed a high-fat / high-fructose diet showed reduced ClpP expression and activity compared to the normal control group, but the experimental group administered A-54556A showed restored ClpP expression and activity despite the supply of a high-calorie diet. Furthermore, it was confirmed that A-54556A can exhibit preventive and therapeutic effects for non-alcoholic fatty liver disease by reducing fatty liver, liver inflammation, liver damage, and liver fibrosis.
[0014] According to U.S. Patent Publication US2016 / 0046674, in which the above-mentioned A-54556A was first disclosed, the antibiotic use of A-54556A is known, but its therapeutic or aggravating effects on steatohepatitis, non-alcoholic steatohepatitis, and liver fibrosis are not known.
[0015] The term "treatment" may mean the alleviation, inhibition of progression, or prevention of a disease or one or more of its symptoms.
[0016] The above A-54556A may be a compound represented by the following chemical formula 1.
[0017] [Chemical Formula 1]
[0018]
[0019] The term “pharmaceuticalally acceptable salt” above means a salt prepared using a specific compound according to one aspect and a relatively non-toxic acid or base. Pharmaceutically acceptable base addition salts may include salts or similar salts of sodium, potassium, calcium, ammonium, organic amine, or magnesium. Pharmaceutically acceptable acid addition salts may include salts of inorganic acids such as hydrochloric acid, hydrobromide, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, or phosphoric acid, and salts of organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, souveric acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, and methanesulfonic acid, and furthermore, salts of amino acids (e.g., arginine, etc.) and salts of organic acids such as glucuronic acid may also be included.
[0020] The above fatty liver disease may be non-alcoholic fatty liver disease (NASH).
[0021] The above A-54556A or its pharmaceutically acceptable salts may be administered in various oral and parenteral formulations for clinical administration. When formulated, they are prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid formulations for oral administration include tablets, pills, powders, granules, and capsules, and these solid formulations are prepared by mixing at least one excipient, e.g., starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, and emulsions. Non-aqueous solvents and suspension agents may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleates.
[0022] A pharmaceutical composition having the above-mentioned A-54556A or a pharmaceutically acceptable salt thereof as an active ingredient may be administered parenterally, and parenteral administration may be carried out by subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection. In this case, to formulate a formulation for parenteral administration, the above-mentioned A-54556A or a pharmaceutically acceptable salt thereof may be mixed with water together with a stabilizer or a buffer to prepare a solution or suspension, and may be prepared in an ampoule or vial unit dosage form. The composition may be sterilized and / or may contain adjuvants such as preservatives, stabilizers, hydrating agents or emulsification promoters, salts and / or buffers for osmotic pressure regulation, and other therapeutically useful substances, and may be formulated according to conventional mixing, granulation, or coating methods. Oral dosage forms include, for example, tablets, pills, hard / soft capsules, liquids, suspensions, emulsifiers, syrups, granules, elixirs, troches, etc., and these dosage forms may contain, in addition to the active ingredient, diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycol). Tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and, in some cases, disintegrants or boiling mixtures such as starch, agar, alginic acid or its sodium salt and / or absorbents, coloring agents, flavoring agents, and sweeteners.
[0023] Another aspect provides a pharmaceutical composition for the treatment or prevention of liver fibrosis comprising A-54556A or a pharmaceutically acceptable salt thereof as an active ingredient.
[0024] The description of A-54556A or its pharmaceutically acceptable salts is the same as described above.
[0026] Another aspect provides a method for treating or preventing fatty liver disease comprising the step of administering A-54556A or a pharmaceutically acceptable salt thereof to an individual.
[0027] The description of A-54556A or its pharmaceutically acceptable salts is the same as that described above.
[0028] The term "administration" above means introducing a specific substance into an individual by an appropriate method, and "individual" means any organism, including humans, rats, mice, livestock, etc., that may carry steatohepatitis or non-alcoholic steatohepatitis. Specifically, it may be mammals, including humans. Routes of administration may include, but are not specifically limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, local, sublingual, or rectal.
[0029] The above A-54556A or its pharmaceutically acceptable salt is administered in a pharmaceutically effective amount. The term "pharmaceuticalally effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. Specifically, the pharmaceutical composition may be administered at a dose of 0.01 to 1000 mg / kg / day, more specifically at a dose of 0.1 to 500 mg / kg / day. The administration may be given once a day or divided into several doses. Specifically, the effective amount of the above pharmaceutical composition may vary depending on the patient's age, gender, condition, body weight, absorption rate, inactivation rate, excretion rate of the active ingredient in the body, type of disease, and concomitant drugs, and may increase or decrease depending on the route of administration, severity of obesity, gender, body weight, age, etc. Effects of the invention
[0031] A-54556A, a ClpP activator, has been confirmed to reduce fatty liver, suppress inflammatory responses, inhibit hepatotoxicity, and inhibit liver tissue fibrosis when administered to an animal model of steatohepatitis; therefore, it can be used for the treatment of steatohepatitis or non-alcoholic steatohepatitis. Brief explanation of the drawing
[0033] Figure 1 shows the preparation process of a high-calorie diet mouse used in an embodiment of the present invention. Figure 2 shows the results confirming that ClpP activity, which was reduced by a high-calorie diet, was restored by the administration of A-54556A. Figure 3 shows the results confirming that ClpP expression, which was reduced by a high-calorie diet, was restored by the administration of A-54556A. Figure 4 shows the results confirming that the increase in fatty liver caused by a high-calorie diet is inhibited by A-54556A. Figure 5 shows the results confirming that the increase in inflammatory cytokine expression in the liver caused by a high-calorie diet is inhibited by A-54556A. Figure 6 shows the results confirming that the increase in phosphorylation of JNK and p65 in liver tissue caused by a high-calorie diet is inhibited by A-54556A. Figure 7 shows the results confirming that the increase in blood AST, ALT levels, and NAS scores caused by a high-calorie diet is inhibited by A-54556A. Figure 8 shows the results confirming that the increased Sirius red staining and increased collagen and TIMP expression caused by a high-calorie diet were reduced by A-54556A. Specific details for implementing the invention
[0034] One or more specific examples are described in more detail below through embodiments. However, these embodiments are intended to illustrate one or more specific examples and the scope of the present invention is not limited to these embodiments.
[0036] Example 1: Preparation of high-calorie diet mice
[0037] The preparation process for high-fat / high-fructose diet mice is described based on Figure 1. Six-week-old male C57BL / 6J mice were obtained from SLC in Japan. These animals were separated into 3-4 individuals per cage at the Animal Laboratory of Ajou University College of Medicine and reared at a temperature of 22±0.5℃ and a humidity of 55±5% on a 12-hour day-night cycle.
[0038] Eight-week-old C57BL / 6J mice were divided into three groups. One group served as a normal control group, receiving a normal diet for 6 weeks and a normal fat diet containing 10% fat (Research diet, D12450) for 6 weeks. (This experimental group can be considered the group that received the normal diet.) The other two groups received high-fat (HF) and high-fructose (HFr) diets for 6 weeks. The high-fat and high-fructose diets contained 60% fat (Research diet, D12492) and 30% fructose. For the two groups fed the above high-fat and high-fructose diet for 6 weeks, one group was fed the high-fat and high-fructose diet for another 6 weeks while receiving intraperitoneal DMSO, and the other group was fed the high-fat and high-fructose diet for another 6 weeks while receiving intraperitoneal A-54556A dissolved in DMSO at a dose of 20 mg / kg. (See Figure 1) Afterward, the mice were sacrificed and liver tissues were isolated and used in the experiment.
[0040] Example 2: Confirmation of ClpP protein expression levels in high-fat / high-fructose diet mice
[0041] 2-1. Measurement of ClpP Activity in Liver Tissue
[0042] After sacrificing mice and isolating liver tissue, ClpP activity in the liver tissue was measured. Mitochondria were isolated from 100 mg of liver tissue using a mitochondrial isolation kit (Thermo Fisher Scientific, Mitochondria Isolation Kit for Tissue, 89801), and ClpP activity was investigated using a Protease Fluorescent Detection Kit (Sigma-Aldrich). Mitochondrial proteins isolated from each group and FITC-casein were added and incubated at RT for 0.5 hours; subsequently, the absorbance of cleaved fluorescein isothiocyanate (FITC) was measured using a SpectraMax®iD3 Multi-Mode Microplate Reader (Molecular Devices) as an ELISA leader (excitation 485 / emission wavelengths 535).
[0044] 2-2. Measurement of ClpP Protein Expression in Liver Tissue
[0045] Proteins were isolated from 100 mg of liver tissue and isolated mitochondria using RIPA buffer (1% triton X-100m, 1% sodium deoxcolate, 50 mM NaCl2, 50 mM tris-HCl, 1 mM sodium vanadate, 2 mM PMSF, protease inhibitor cocktail (Roche Applied Science)). After quantification, the proteins were diluted in sample buffer (50 mmol / l Tris-HCl at pH 6.8, 2% SDS, 100 mmol / l DL-dithiothreitol, 10% glycerol), heated for 5 minutes, loaded onto an 8 to 12% SDS-polyacrylamid gel for electrophoresis, transferred to a PVDF membrane, and blocked with 5% skim milk. After reacting with the primary antibody listed in Table 1 below, a secondary antibody suitable for the conditions was reacted, and the bands were visualized using an enhanced chemiluminescence system (Pierce, Rockford, IL, USA). The bands were One-Dimensional Quantity One ® Quantification was performed using a 1D image analysis program (Bio-Rad, Hercules, CA).
[0046] Name Catalog number Company Name ClpP ab124822 Abcam Gfm1 A5077 ABclonal ATP5a ab14748 Abcam VDAC ab14734 Abcam Tubulin SC5286 Santacruz Biotechnology
[0047] 2-3. Experimental Results
[0048] According to Figures 2 and 3, both ClpP protein expression and activity were reduced in the liver tissue of mice fed a high-fat / high-fructose diet. Also, the expression levels of Gfm1 and Atp5a, which are known to be degraded by ClpP, increased.
[0049] However, in the liver tissues of mice fed a high-fat / high-fructose diet administered A-54556A, ClpP expression and activity increased, and the expression levels of Gfm1 and Atp5a also decreased to normal levels.
[0051] Example 3: Confirmation of the liver fat-reducing effect of A-54556A
[0052] 3-1. Measurement of Liver Triglycerides (liver TG)
[0053] To measure the amount of fat accumulation in liver tissue, 100 mg of liver tissue isolated from mice was homogenized in 1 ml of 5% NP-40 DW. Triglycerides (TG) were extracted by slowly heating the samples to 80–100°C in a water bath for 2–3 minutes. Once the buffer became turbid due to the extracted TG, the samples were allowed to cool naturally at room temperature, and the extraction process was repeated 2 to 3 times. The samples were centrifuged to precipitate insoluble tissue, and the supernatant containing TG was obtained. The TG concentration in the liver tissue was measured using a Triglyceride Quantification kit (K-622-100 / Biovision).
[0055] 3-2. Hematoxylin-Eosin (H&E) Staining
[0056] Liver tissue obtained from mice was fixed with 4% paraformaldehyde at 4°C for 24 hours, washed under running water, and then paraffin-embedded and microtome-cut into 10 μm thick sections. The sectioned tissues were attached to coated slides, paraffin was removed with xylen, and the tissues were hydrated in the order of 100% ethanol, 95% ethanol, 90% ethanol, 80% ethanol, and 70% ethanol before performing immunohistological staining. The sectioned tissues were stained with Harry's hematoxylin solution for 5 minutes, washed under running water for 5 minutes, and destained with 1% HCl alcohol and ammonia. Subsequently, the tissues were washed under running water for 10 minutes, counterstained with eosin solution for 1 minute, and dehydrated in the reverse direction of the hydration process before being mounted and observed under a microscope (Olympus, Tokyo, Japan).
[0058] 3-3. Oil-red O staining
[0059] The isolated tissues were washed, dried, and fixed in Optical Cutting Temperature (OCT) compound (SAKURA, USA), a frozen tissue embedding agent, to create frozen tissue blocks, which were then stored in a -70°C freezer. Liver tissues were cut into 10 µm thick sections using a microtome, rapidly attached to slides, dried at room temperature for about 1 hour, and then stored in a -70°C deep freezer. 3 g / L of Oil-red-O (Sigma, USA) powder was added to a 99% isopropanol solution and shaken at room temperature to prepare a saturated solution; this solution was then stored in a 60°C oven, and immediately before staining, a solution of the saturated solution and distilled water mixed in a 6:4 ratio was filtered through Whatman Filter Paper #2 (Whatman, England) for use. Slides stored in the -70°C deep freezer were removed immediately before the experiment, dried at room temperature for about 1 to 2 hours, then washed with water and rinsed in 70% isopropanol for 10 minutes. Slides were placed in filtered Oil-red-O and stained for 15 minutes, then placed in 70% isopropanol and destained for 3 minutes. The slides were then rinsed under running water for 5 minutes, stained in hematoxylin solution (Sigma, USA) for 5 minutes, and rinsed again under running water for 5 minutes. After staining, the slides were sutured with Faramount Aqueous Mounting Medium (Dako. cat. S3025, Japan) and observed under a microscope.
[0060] 3-4. Experimental Results
[0061] According to Figure 4A, fatty liver in mice on a high-fat / high-fructose diet increased by approximately 6 times compared to the normal control group. However, in mice administered A-54556A, fatty liver formation was inhibited despite the high-fat / high-fructose diet.
[0062] To further confirm the fatty liver-reducing effect of A-54556A, liver tissues were stained with Hematoxylin-Eosin (H&E) and Oil Red O, and the experimental group and the control group were compared. According to Figure 4B, the fatty liver in the liver tissues of mice administered A-54556A was reduced compared to the experimental group fed only a high-fructose / high-fat diet.
[0064] Example 4: Inhibitory effect of A-54556A on fatty liver hepatitis
[0065] 4-1. Macrophage Tissue Staining
[0066] To measure the morphology of liver tissue, liver tissue obtained from mice was fixed with 4% paraformaldehyde at 4°C for 24 hours, washed with running water, embedded in paraffin, and sectioned to a thickness of 5 µm. The sectioned tissue was attached to a coated slide, paraffin was removed with xylen, and the tissue was hydrated in the order of 100% ethanol, 95% ethanol, 90% ethanol, 80% ethanol, and 70% ethanol. Immunohistological staining with F4 / 80 antibody was performed, followed by counterstaining. After dehydration in the reverse direction of the hydration process, the tissue was mounted and observed under a microscope (Olympus, Tokyo, Japan).
[0068] 4-2. qRT-PCR
[0069] To measure the morphology of liver tissue, mice were sacrificed and livers were excised; RNA was then extracted and quantified using RNA TRI Zol. 2 µg of RNA was mixed with 0.5 µl of 1000 U AMV reverse transcriptase, 4 µl of 2.5 mM dNTPs, 1 µl of Random 9 mer, 0.5 µl of RNase inhibitor, 4 µl of MgCl2, and 2 µl of 10X RT buffer, and cDNA was synthesized by performing a reverse transcription reaction at 30°C for 10 minutes, 42°C for 30 minutes, and 99°C for 5 minutes. Using the cDNA obtained in this way, qPCR was performed with the primers listed in Table 2 below and the Takara qPCR kit (Cybergreen).
[0071] Primer Name Forward (5'-3') Reverse (5'-3') rpl32 AAGCGAAACTGGCGGAAACC CCCATAACCGATGTTGGGCA f4 / 80 CCCGTGTTGTTGGTGGCACT GCTTTGGCTGGATGTGCTGG il-1β TCTCGCAGCAGCACATCAACA CCTGGAAGGTCCACGGGAAA mcp-1 CAGCCAGATGCAGTTAACGC GCCTACTCATTGGGATCATCTTG
[0072] 4-3. Investigation of Inflammatory Mechanisms (p-JNK, p-p65)
[0073] 100 mg of liver tissue was placed in RIPA buffer (1% triton X-100m, 1% sodium deoxcolate, 50 mM NaCl2, 50 mM tris-HCl, 1 mM sodium vanadate, 2 mM PMSF, protease inhibitor cocktail (Roche Applied Science)), and proteins were isolated after lysis. After quantification, the proteins were diluted in sample buffer (50 mmol / l Tris-HCl at pH 6.8, 2% SDS, 100 mmol / l DL-dithiothreitol, 10% glycerol), heated in hot water for 5 minutes, and then subjected to electrophoresis on an 8 to 12% SDS-polyacrylamid gel to transfer the proteins to a PVDF membrane, which was then blocked with 5% skim milk. After reacting each primary antibody, a condition-appropriate secondary antibody was reacted, and the bands were visualized using an enhanced chemiluminescence system (Pierce, Rockford, IL, USA). The bands were One-Dimensional Quantity One ® Quantification was performed using a 1D Image Analysis program (Bio-Rad, Hercules, CA). The antibodies used in the experiment are listed in Table 3 below.
[0074] Name Catalog number Supplier phospho-JNK 9251 cell signaling Total-JNK sc-474 Santa Cruz phospho-p65 3033 cell signaling Total-p65 3034 cell signaling Tubulin sc5286 Santa Cruz
[0076] NASH progresses from fatty liver to steatohepatitis, and unlike simple fatty liver, inflammatory cells infiltrate liver tissue, causing inflammation and disrupting the function of liver cells.
[0077] When examining the inflammatory cytokine and immune cell infiltration status of C57BL / 6J mice fed a high-fat and high-fructose diet and the experimental group administered A-54556A along with the high-fat and high-fructose diet, the difference was clear. According to Figure 5, the mRNA levels of inflammatory cytokines such as IL-1beta and MCP-1 were significantly increased in the liver tissue of mice fed the high-fat and high-fructose diet. However, the mRNA levels of inflammatory cytokines (IL-1beta, MCP-1) were significantly decreased in the liver tissue of the group administered A-54556A.
[0078] In addition, to investigate macrophage infiltration, which is known to secrete inflammatory cytokines, liver tissue was stained with F4 / 80. The results showed that macrophage infiltration significantly increased in the livers of mice fed a high-fat and high-fructose diet, whereas macrophage infiltration significantly decreased in mice treated with A-54556A. Based on these results, it was found that the A-54556A administration group had an efficacy in improving fatty liver inflammation compared to the control group.
[0079] To investigate the mechanism of inflammation suppression, the phosphorylation of JNK and p65, known as representative stress signals, was examined. According to Figure 6, the phosphorylation of JNK and p65 increased in the liver tissues of mice fed a high-fat and high-fructose diet. However, the phosphorylation of JNK and p65 was significantly reduced in the experimental group administered A-54556A.
[0081] Example 5: Inhibitory effect of A-54556A on hepatocellular damage
[0082] Mice were sacrificed, and blood AST and ALT levels were measured. According to Figure 7A, the blood AST and ALT levels of mice fed a high-fat and high-fructose diet increased significantly compared to the control group. This result indicates that mice fed a high-calorie diet experienced increased liver cell damage compared to mice fed a normal diet. However, the AST and ALT levels of the experimental group administered A-54556A along with the high-calorie diet decreased significantly compared to the animal group fed only a high-fructose and high-fat diet.
[0083] To further confirm the hepatoprotective effect of A-54556A, each tissue was stained with Hematoxylin-Eosin (H&E), and NAS scores such as steatosis, ballooning, and lobular inflammation were compared. According to Figure 7B, it was confirmed that the liver tissue of mice administered A-54556A showed a decrease in NAS score (NAFLD activity score, non-alcoholic fatty liver disease score) compared to the experimental group administered only a high-fructose and high-fat diet.
[0085] Example 6: Inhibitory effect of A54556A on liver fibrosis
[0086] We investigated whether liver fibrosis progressed in C57BL / 6J mice fed a high-fructose and high-fat diet for 12 weeks using Sirius Red staining.
[0087] Unlike simple fatty liver, NASH involves inflammatory cells infiltrating liver tissue to induce inflammation and enlarge the volume of liver cells compared to normal size; as the disease progresses, it leads to fibrosis of the liver tissue. The most important cells contributing to liver fibrosis are hepatic stellate cells (HSCs), which account for 15% of liver cells. Damaged liver cells or immune cells secrete PDGF or TGF-beta1 to activate hepatic stellate cells, and these activated cells transform into myofibroblast-like cells that secrete extracellular matrix components such as type I collagen and type III collagen, which accumulate to drive liver fibrosis.
[0088] 5-1. qRT-PCR
[0089] After sacrificing the mice of the experimental group and extracting their livers, RNA was extracted and quantified using RNA TRI Zol. 2 µg of RNA was mixed with 0.5 µl of 1000 U AMV reverse transcriptase, 4 µl of 2.5 mM dNTP, 1 µl of Random 9 mer, 0.5 µl of RNase inhibitor, 4 µl of MgCl2, and 2 µl of 10X RT buffer, and cDNA was synthesized by performing a reverse transcription reaction at 30°C for 10 minutes, 42°C for 30 minutes, and 99°C for 5 minutes. Using the cDNA obtained in this way, qPCR was performed using the primers listed in Table 4 below and the Takara qPCR kit (Cybergreen).
[0090] Name Forward (5'-3') Reverse (5'-3') timp ACGCCAGGGAACCAAGAAGC CCACAAGTCCCAGAACCGCA ctgf CTTTCTGGCTGCACCAGTGT GGCAGAGTGGTGGTTCTGTG col1a2 CTGGGTGAACCTGGTCCTCT ACCAGGGGCACCATTAACTC col3a1 GTCCAAAGGGTGAAGTCGGT CAGCTCCACCTCTAGCACCA
[0092] 5-2. Sirius Red Staining
[0093] Mice from the experimental group were sacrificed, their livers were excised, and fixed in 4% paraformaldehyde at 4°C for 24 hours. After washing with running water, the tissues were embedded in paraffin and sectioned to a thickness of 5 μm. The sectioned tissues were attached to coated slides, paraffin was removed with xylen, and the slides were hydrated in the order of 100% ethanol, 95% ethanol, 90% ethanol, 80% ethanol, and 70% ethanol. Histological staining and counterstaining were performed with Picro-Sirius Red for 1 hour. After dehydration in the reverse order of the hydration process, the slides were mounted and observed under a microscope (Olympus, Japan).
[0095] According to Figure 8, Sirius Red staining was significantly increased in the liver tissues of mice fed a high-fructose and high-fat diet. Furthermore, in the liver tissues of mice fed a high-fructose and high-fat diet, the expression levels of type I collagen (col1a2) and type III collagen (col3a1), which are involved in fibrosis, and the expression of TIMP (Tissue inhibitor of metalloproteinases), which inhibits MMPs (Matrix metalloproteinases) that promote cytoplasmic degradation, were increased. These results suggest that mice fed a high-fructose and high-fat diet exhibit increased liver fibrosis due to the scarring process following liver injury. However, in the liver tissues of mice administered A-54556A along with a high-fat and high-fructose diet, the expression of Timp, ctgf, col1a2, and col3a1 was significantly reduced, and Sirius Red staining was decreased. Therefore, it was confirmed that A-54556A significantly reduces liver tissue fibrosis.
Claims
Claim 1 A method for treating or preventing fatty liver disease, comprising the step of administering to an individual other than a human a composition comprising A-54556A or a pharmaceutically acceptable salt thereof as an active ingredient, wherein A-54556A is a compound represented by the following chemical formula 1, and A-54556A is (4R)-N-[(2E,4E,6E)-1-oxo-2,4,6-octatrien-1-yl]-L-phenylalanyl-L-seryl-L-prolyl-N-methyl-L-alanyl-L-alanyl-4-methyl-L-proline, (6→2)-lactone [Chemical Formula 1]
Citation Information
Patent Citations
Methods for treating cancer with acyldepsipeptide analogs
WO2019227240A1
